ERBB2 and colorectal cancer: Genetic alterations in ERBB2 have been established as a biomarker for targeted anti-human epidermal growth factor receptor 2 (HER2) therapy in patients with multiple types of solid tumors, including gastrointestinal malignancies such as gastroesophageal, gastric, and colorectal cancers.35,36